Neutralizing monoclonal antibodies against highly pathogenic coronaviruses.
Curr Opin Virol
; 53: 101199, 2022 04.
Article
in English
| MEDLINE | ID: covidwho-1588012
ABSTRACT
The pandemic of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) is a continuing worldwide threat to human health and social economy. Historically, SARS-CoV-2 follows SARS and MERS as the third coronavirus spreading across borders and continents, but far more dangerous with long-lasting symptomatic consequences. The current situation is strong evidence that coronaviruses will continue to be pathogens of consequence in the future, thus calling for the development of neutralizing antibody-based prophylactics and therapeutics for prevention and treatment of COVID-19 and other human coronavirus diseases. This review summarized the progresses of developing neutralizing monoclonal antibodies against infection of SARS-CoV-2, SARS-CoV, and MERS-CoV, and discussed their potential applications in prevention and treatment of COVID-19 and other human coronavirus diseases.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Middle East Respiratory Syndrome Coronavirus
/
COVID-19
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Curr Opin Virol
Year:
2022
Document Type:
Article
Affiliation country:
J.coviro.2021.12.015
Similar
MEDLINE
...
LILACS
LIS